HTLV-1, Immune Response and Autoimmunity

Juarez A S Quaresma 1,†, Gilberto T Yoshikawa 2,†, Roberta V L Koyama 1,†, George A S Dias 1,†, Satomi Fujihara 3,† and Hellen T Fuzii 3,*,†

Received: 18 October 2015; Accepted: 14 December 2015; Published: 24 December 2015
Academic Editor: Louis M. Mansky

1 Science Center of Health and Biology, Pará State University, Rua Perebebuí, 2623, Belém, Pará 66087-670, Brazil; juarez@ufpa.br (J.A.S.Q.); robertakoyamareumato@gmail.com (R.V.L.K.); georgealbertodias@yahoo.com.br (G.A.S.D.)
2 Science Health Institute, Federal University of Pará, Praça Camilo Salgado, 1, Belém, Pará 66055-240, Brazil; gyoshikawa@uol.com.br
3 Tropical Medicine Center, Federal University of Pará, Av. Generalíssimo Deodoro, 92, Belém, Pará 66055-240, Brazil; satomifujihara@gmail.com
* Correspondence: hellenfuzii@gmail.com; Tel.: +55-91-3201-0954
† These authors contributed equally to this work.

Abstract: Human T-lymphotropic virus type-1 (HTLV-1) infection is associated with adult T-cell leukemia/lymphoma (ATL). Tropical spastic paraparesis/HTLV-1-associated myelopathy (PET/HAM) is involved in the development of autoimmune diseases including Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), and Sjögren’s Syndrome (SS). The development of HTLV-1-driven autoimmunity is hypothesized to rely on molecular mimicry, because virus-like particles can trigger an inflammatory response. However, HTLV-1 modifies the behavior of CD4⁺ T cells on infection and alters their cytokine production. A previous study showed that in patients infected with HTLV-1, the activity of regulatory CD4⁺ T cells and their consequent expression of inflammatory and anti-inflammatory cytokines are altered. In this review, we discuss the mechanisms underlying changes in cytokine release leading to the loss of tolerance and development of autoimmunity.

Keywords: Human T-lymphotropic virus type-1 (HTLV-1); immune response; autoimmunity

1. Introduction

The etiology of autoimmune diseases is unknown, but it is clear that the interaction between genes and the environment is an important step in breaking immune tolerance to self-antigens. This can lead to inflammation and destruction of specific tissues and organs. Although host genetic background contributes to autoimmunity, research indicates that infectious agents are one of most important environmental factors responsible for the development of autoimmune diseases [1–3]. Chronic inflammatory responses to infections have been associated with the initiation and exacerbation of autoimmune diseases [1,4,5].

Human T-lymphotropic virus type-1 (HTLV-1) is associated to a number of diseases, such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), and autoimmune diseases such as the Sjögren’s Syndrome (SS), arthropathies, and uveitis, which are often related to changes in the immune response [6–9]. The HTLV-1 virus infects CD4⁺ T lymphocytes, and can modify the cell function. CD4⁺ T lymphocytes are the central acquired immune response regulators. Changes in their behavior can trigger inflammatory reactions that can break immune system tolerance, leading to autoimmunity. In this review, we discuss immunological changes in HTLV-1 infection and its association with autoimmune diseases.
2. Human T-lymphotropic Virus Type-1 (HTLV-1)

Human T-lymphotropic virus type-1 (HTLV-1) is classified as a complex type C retrovirus belonging to the genus Deltaretrovirus, family Retroviridae, and subfamily Orthoretrovirinae [10,11].

The morphological structure of this virus is similar to other retroviruses; the capsid contains two simple RNA strands together with the reverse transcriptase and integrase enzymes. These enzymes are important for insertion of the virus into the host genome, resulting in a provirus [12–15].

The virus genome contains structural and functional genes, such as the gag, pro/pol, and env that are flanked by two long terminal repeat (LTR) regions. Additionally, the pX region was identified in the region between the env gene and the 3’-LTR region. The pX region codes for the Tax (p40), REX (p27), p12, p13, p21, and p30 regulatory proteins that are involved in viral infection and proliferation. Tax is a phosphoprotein that exerts an essential role in viral transcription and cell behavior transformation [16–19]. It has pleiotropic functions that occur on a very wide spectrum of interactions with cellular proteins. Tax can modify signal transduction pathways of the host–cell that induce the transcription factors NF-κB, cAMP response element binding (CREB), Serum response factor (SRF) and activator protein 1 (AP-1) [12,13,20–22].

Recently, another gene was identified, hbz (HTLV-1 b-ZIP factor), that codes for a protein involved in the pathogenesis of the virus together with Tax. HBZ can function in two different molecular forms, mRNA and protein. In mRNA form, it can promote cell proliferation by positive regulation of E2F1. HBZ protein can down-regulate Tax expression and can interact directly with c-Jun and c-Jun-B [23,24].

HTLV-1 infection is associated with several diseases, primarily with adult T-cell lymphoma (ATL) and HAM/TSP. HAM/TSP patients present a series of immunological dysfunctions, including spontaneous proliferation of HTLV-infected T CD4+ lymphocytes, an increase in the migratory capacity of circulating leukocytes, and increased production of inflammatory cytokines—particularly neurotoxic cytokines such as IFN-γ and TNF-α—in affected regions along the spinal cord [6,16,25–28]. In HAM/TSP patients, there is a predominance of Th1 cytokines (IFN-γ) and a reduction in Th2 cytokines (IL-4 and IL-10), this is likely to cause greater circulation of immune cells between peripheral blood and the central nervous system (CNS), leading to inflammation of the nervous tissue [29–31]. Among the several existing theories related to HAM/TSP development, the most widely accepted is that it is a virally induced, cytotoxic, demyelinating inflammatory process of a chronic and progressive nature. The lymphocytes are activated during spastic paraparesis; when they cross the blood–brain barrier, the inflammatory process initiates in the CNS, resulting in lesions [10,15,26,32,33]. Another theory is direct cytotoxicity mechanism, where HTLV-1-cytotoxic CD8+ T cell cross the blood-brain barrier and destroy HTLV-1 infected glia cells by cytotoxicity or cytokine production. The last theory suggests that autoimmunity mechanism can cause lesions by molecular mimicry. A host neuronal protein seems to be similar to Tax protein from the virus, which can cause immune cross-reaction, leading to CNS inflammation [6,10,34,35].

3. Immunological Changes in HTLV-1-Infected Patients

Patients infected with HTLV-1 may develop a number of associated diseases, such as HAM/TSP, or other autoimmune diseases such as the Sjögren’s Syndrome (SS), arthropathies, and uveitis, which are often related to changes in the immune response [7–9,35]. These changes may occur due to infection of the CD4+ T lymphocytes by HTLV-1.

HTLV-1-infected CD4+ T lymphocytes exhibit altered signaling cascades and transcription factor activation, leading to changes in cell behavior [7–9,16,36,37].

Many studies have reported that the HTLV-1 Tax protein affects several transcription factors including CREB/ATF, NF-kB, AP-1, SRF, and Nuclear factor of activated T-cells (NFAT), as well as a number of signaling cascades involving PDZ domain-containing proteins such as Rho-GTPases and Janus kinase (JAK)/signal transducer and activator of transcription (STAT), thus altering the
transforming growth factor-β (TGF-β) cascades. These factors are involved in cell proliferation and activation, including expression of cytokines and activation of viral proteins [17–19,38–41].

The expression of forkhead/winged helix transcription factor (FOXP3), which is an important transcription factor, has also been reported to be altered in patients infected with HTLV-1. FOXP3 is an essential transcription factor for the differentiation, function, and homeostasis of regulatory T cells (Tregs). Irregularities in the expression of FOXP3 may lead to loss of immune tolerance and the probable development of autoimmune diseases [41,42].

Previous studies have demonstrated that an increase in FOXP3 expression in patients that developed ATL leads to an exacerbated Treg function, resulting in increased production of IL-10 and TGF-β, which in turn triggers the immunosuppression phenotype observed in these patients. In contrast, studies performed with patients that developed HAM/TSP showed a decrease in FOXP3 expression and in the production of the IL-10 and TGF-β cytokines responsible for suppression of the immune response [31,36,43–45]. This loss of suppressive function may lead to an exacerbation of the disease process, since inflammation is not controlled and the inflammatory process is perpetuated. A study performed by Yamano et al. [31] showed that persistent activation of the immune response, induced by Tax, in patients with HAM/TSP may be associated with a decrease in the expression of CD4+CD25+FOXP3+ T cells that possess a suppressive function and an accumulation of CD4+CD25−FOXP3− T cells that can exacerbate the pathogenic process of HAM/TSP. The authors demonstrated that in patients with HAM/TSP, there was an increase in the sub-population of IFN-γ-producing T cells with a CD4+CD25−FOXP3− phenotype and that this increase correlated with the clinical severity of HAM/TSP.

Changes in signaling pathways and transcription factor activation caused by viral proteins play an important role in modifying immune response homeostasis, resulting in a cytokine environment that may influence the immune cells phenotype. The effect of the environment may lead to autocrine and paracrine activation and thus influence T cell differentiation and homeostasis. IFN-γ can stimulate the production of Th1 cells, while the presence of IL-4 leads to the differentiation of Th2 cells. Several studies have shown that the presence of these cytokines triggers the activity of known suppressors of cytokine signaling (SOCS) family proteins, which are able to inhibit the recruitment of STATs or the activation of JAKs. SOCS play a role in the maturation, differentiation, and maintenance of T lymphocytes [46–48]. SOCS-1 was shown to inhibit the activation of pathways stimulated by IFN-γ and IL-4, whereas SOC3 is important for maintaining the Th2 phenotype. Previous studies performed with HAM/TSP patients have demonstrated increased SOC-1 and decreased SOC-3 levels, suggesting a tendency towards the Th1 response [49].

The HTLV-1-infected CD4+ T lymphocytes of HAM/TSP patients exhibit spontaneous proliferation, in addition to an increased production of proinflammatory cytokines such as IFN-γ, TNF-α, IL-1, and IL-6; neurotoxic cytokines such as IFN-γ and TNF-α, in particular, are found at high concentrations in the spinal fluid of HAM/TSP patients [9,16,50,51]. These findings demonstrate that infected individuals have an immune response characteristic of the Th1 phenotype (IFN-γ and TNF-α) and a decrease in the Th2 profile (IL-4 and IL-10) [30,31,45].

Toulza et al. [43] observed that individuals with HAM/TSP had similar IL-10 levels as healthy individuals and that the TGF-β levels were significantly lower compared to the control group; this in turn could result in a decrease in the Treg cell-mediated suppressive function and thus contribute to the exacerbation of inflammation.

4. HTLV-1 and Autoimmunity

HTLV-1 infection leads to changes in the systemic immune response even in asymptomatic patients [36,52–57]. The regulation of the immune response is carefully organized so that the organism suffers no damage and that homeostasis is maintained. This is ensured via clonal selection that occurs during lymphocyte development concomitant with the destruction of the autoreactive cells [58] and the development of Treg cells. Treg cells are able to inhibit the proliferation of T cells in vitro and
regulate the activity of CD4+ and CD8+ T cells \textit{in vivo}. There are two major types of Treg cells, naturally occurring cells and cells produced in the periphery [59].

During the development of autoimmunity, there is a loss of tolerance to self-antigens, causing an inflammatory response that attacks organs and tissues of the individual. The pathogenesis of autoimmune diseases is generally studied in the context of T helper cells and the balance between the Th1 and Th2 responses. Thus, it has been observed that some diseases such as Rheumatoid Arthritis (RA) fit the Th1 profile, in which a cell-mediated response occurs, while others such as Systemic Lupus Erythematosus (SLE) fit the Th2 profile, involving antibodies and immunocomplexes in their physiopathology [60]. However, during the development of autoimmunity, there is a combination of several factors that are not only immunological, but also genetic and environmental [61,62]. Of these environmental factors, infections are of great importance, since they act as a trigger for autoimmunity [63,64].

The association between autoimmunity and HTLV-1 infection has been previously described; however, the mechanisms underlying this association are not yet fully understood. Many studies have indicated that molecular mimicry could be the trigger for the development of certain diseases. However, as previously described, HTLV-1 can result in several immune response anomalies since it infects CD4+ T lymphocytes and alters their behavior (Figure 1) [65,66].

\begin{figure}[h]
\centering
\includegraphics[width=0.5\textwidth]{htlv-autoimmunity.png}
\caption{Possible mechanisms involved in HTLV-1 association with autoimmunity.}
\end{figure}

5. Rheumatoid Arthritis

RA is a chronic and incapacitating disease that affects 1% of the world’s population. Although the etiopathology of the disease is not fully understood, it is characterized by chronic polyarthritis that may lead to the destruction of articulation if not properly treated [67–71]. During the early stages of RA, the cytokines expressed in the synovium are mainly IL-2, 4, 13, 15, and 17. Once the disease is established, expression of IFN-\(\gamma\), TNF-\(\alpha\), and IL-10 is observed, with low-level expression of IL-2, -4, -5, and -13. Furthermore, there is a correlation between serum cytokines and disease progression [72,73]. The development and progression of RA depends on the migration of the T lymphocytes into the synovium. Previous studies have observed proliferation of the synovium and T cell infiltration in HTLV infected patients that develop RA. Several studies reported the presence of HTLV proviral DNA in synovial liquid and tissue cells and that T cells in both the synovium and synovial cells were infected with HTLV-1. Nishioka \textit{et al.} [74] also reported the expression of Tax mRNA in synovial cells from HTLV-I-associated arthropathy patients. Tax may induce cell proliferation, as well as the production of inflammatory cytokines. In addition, similar to what occurs in HAM/TSP, there is a migration of lymphocytes into the CNS. This migration may be associated with the viral load of the patient, as demonstrated by Yakova \textit{et al.} [75]. These authors observed that patients infected with HTLV-1 that had RA or connective tissue disease had a higher viral load compared to asymptomatic patients; however, it was similar to the viral load of patients that developed HAM/TSP. Moreover, the viral load in the synovium was higher in RA patients [74–79].
6. Sjögren’s Syndrome

SS is defined as a systemic autoimmune disorder, manifesting primarily as xerostomia (dry mouth) and xerophthalmia (dry keratoconjunctivitis) due to the lymphocytic infiltration of the salivary and lachrymal glands, which in turn leads to the destruction of the ducts. Furthermore, antinuclear antibodies (ANA) and other self-antibodies, such as anti-SS-A (Ro) and SS-B (La), are also found in these patients. Disease development is also associated with genetic and hormonal factors [80,81]. Several viral infections, such as HTLV-1, may also be associated with the occurrence of this disease. A number of studies have reported a high prevalence of HTLV-1 in SS patients [82,83]. Nakamura et al. [84] reported a high prevalence of anti-HTLV-1 IgA in the salivary glands of SS patients. Another interesting related factor is the level of mononuclear infiltrate in SS patients infected with HTLV-1; SS patients with HTLV-1 show higher infiltrate levels compared with SS patients not infected with HTLV-1 [82–84].

7. Systemic Lupus Erythematosus

SLE is a systemic autoimmune disease of unknown etiology. This disease progresses with polymorphic clinical manifestations and periods of exacerbation and remission. Disease development is associated with a genetic predisposition and environmental factors, such as exposure to sunlight and viral infection [85–88].

The association between HTLV-1 and SLE is still controversial [89–91]. One possible mechanism proposed for this association is a process of molecular mimicry through the endogenous sequence related to HTLV-1 (HRES-1) in the development of SLE. This could trigger the production of self-antibodies, leading to the formation of immunocomplexes that are deposited in the tissues; this in turn could cause complement fixation and inflammation, which are pathogenic characteristics of SLE [92]. Other studies have demonstrated the expression of HTLV-1 antigens in the mononuclear cells present in the peripheral blood of individuals with SLE and infected with HTLV-1, following three or more days of in vitro culturing. This indicates the occurrence of viral replication in SLE patients, which could explain the high seropositivity for HTLV-1 and HTLV-2 observed in these patients [93].

8. Conclusions

Several studies have described HTLV-1 infection in the context of autoimmune diseases, although this subject is still under debate. Molecular mimicry has been hypothesized as a possible mechanism; however, HTLV-1-promoted altered cytokine release is critically involved in breaking tolerance. HTLV-1-induced changes in the activity of regulatory CD4 T-cell molecules affect the homeostasis of cytokines, including IFN-γ, TNF-α, TGF-β and IL-10, and disrupt the balance in inflammatory and anti-inflammatory responses, leading to the loss of tolerance and the development of autoimmunity.

Acknowledgments: We thank Federal University of Pará and Pará State University for supporting our work.

Author Contributions: Juarez A S Quaresma, Gilberto T Yoshikawa, George A S Dias, Roberta V L Koyama, Satomi Fujihara and Hellen T Fuzii, wrote the review with equal contribution.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Von Herrath, M.G.; Fujinami, R.S.; Whitton, J.L. Microorganisms and autoimmunity: Making the barren field fertile? Nat. Rev. Microbiol. 2003, 1, 151–157. [CrossRef] [PubMed]
2. Libbey, J.E.; Fujinami, R.S. Potential triggers of MS. Results Probl. Cell Differ. 2010, 51, 21–42.
3. Fujinami, R.S. Viruses and autoimmune disease—Two sides of the same coin? Trends Microbiol. 2001, 9, 377–381. [CrossRef]
4. McCoy, L.; Tsunoda, I.; Fujinami, R.S. Multiple sclerosis and virus induced immune responses: Autoimmunity can be primed by molecular mimicry and augmented by bystander activation. *Autoimmunity* 2006, 39, 9–19. [CrossRef] [PubMed]

5. Sfriso, P.; Ghirardello, A.; Bottsios, C.; Tonon, M.; Zen, M.; Bassi, N.; Bassetto, F.; Doria, A. Infections and autoimmunity: The multifaceted relationship. *J. Leukoc. Biol.* 2010, 87, 385–395. [CrossRef] [PubMed]

6. Araujo, A.Q.; Silva, S.T. The HTLV-1 neurological complex. *Lancet Neurol.* 2006, 5, 1068–1076. [CrossRef]

7. Gessain, A.; Barin, F.; Vernant, J.C.; Gout, O.; Maurs, L.; Calender, A.; de Thé, G. Antibodies to human T lymphotropic virus type 1 in patients with tropical spastic paraparesis. *Lancet* 1985, 2, 407–410. [CrossRef]

8. Román, G.C.; Osame, M. Identity of HTLV-I-associated tropical spastic paraparesis and HTLV-I-associated myelopathy. *Lancet* 1988, 1. [CrossRef]

9. Romanelli, L.C.F.; Caramelli, P.; Proietti, A.B.F.C. Human T-cell leukemia virus type 1 (HTLV-1): When do we suspect of infection? *Rev. Assoc. Med. Brás.* 2010, 56, 340–347. [CrossRef] [PubMed]

10. Cooper, S.A.; van der Loeff, M.S.; Taylor, G.P. The neurology of HTLV-1 infection. *Pract. Neurol.* 2009, 9, 16–26. [CrossRef] [PubMed]

11. Gessain, A.; Mahieux, R. Tropical spastic paraparesis and HTLV-1 associated myelopathy: Clinical, epidemiological, virological and therapeutic aspects. *Rev. Neurol.* 2012, 168, 257–269. [CrossRef] [PubMed]

12. Boxus, M.; Willems, L. Mechanisms of HTLV-1 persistence and transformation. *Br. J. Cancer* 2009, 101, 1497–1501. [CrossRef] [PubMed]

13. Hoshino, H. Cellular factors involved in HTLV-1 entry and pathogenicity. *Front. Microbiol.* 2012, 3. [CrossRef] [PubMed]

14. Lairmore, M.D.; Anupam, R.; Bowden, N.; Haines, R.; Haynes, R.A., II; Ratner, L.; Green, P.L. Molecular determinants of human T-lymphotropic virus type 1 transmission and spread. *Viruses* 2011, 3, 1131–1165. [CrossRef] [PubMed]

15. Matsuura, E.; Yamano, Y.; Jacobson, S. Neuroimmunity of HTLV-I Infection. *J. Neuroimmune Pharmacol.* 2010, 5, 310–325. [CrossRef] [PubMed]

16. Best, I.; López, G.; Verdonck, K.; González, E.; Tipismana, M.; Gotuzzo, E.; Vanham, G.; Clark, D. IFN-γ production in response to Tax 161-233, and frequency of CD4+ Foxp3+ and Lin HLA-DRhigh CD123+ cells, discriminate HAM/TSP patients from asymptomatic HTLV-1-carriers in a Peruvian population. *Immunology* 2009, 128, e777–e786. [CrossRef] [PubMed]

17. Marriott, S.J.; Semmes, O.J. Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response. *Oncogene* 2005, 24, 5986–5995. [CrossRef] [PubMed]

18. Grassmann, R.; Aboud, M.; Jeang, K.T. Molecular mechanisms of cellular transformation by HTLV-1 Tax. *Oncogene* 2005, 24, 5976–5985. [CrossRef] [PubMed]

19. Cheng, H.; Ren, T.; Sun, S.C. New insight into the oncogenic mechanism of the retroviral oncoprotein Tax. *Protein Cell* 2012, 3, 581–589. [CrossRef] [PubMed]

20. Higuchi, M.; Fujii, M. Distinct functions of HTLV-1 Tax1 from HTLV-2 Tax2 contribute key roles to viral pathogenesis. *Retrovirology* 2009, 6. [CrossRef] [PubMed]

21. Jeang, K.T. HTLV-I and adult T-cell leukemia: Insights into viral transformation of cells 30 years after virus discovery. *J. Formos. Med. Assoc.* 2010, 109, 688–693. [CrossRef]

22. Beimling, P.; Moelling, K. Direct interaction of CREB protein with 21 bp Tax-response elements of HTLV-ILTR. *Oncogene* 1992, 7, 257–262. [PubMed]

23. Satou, Y.; Yasunaga, J.; Yoshida, M.; Matsuoka, M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. *Proc. Natl. Acad. Sci. USA* 2006, 103, 720–725. [CrossRef] [PubMed]

24. Matsuoka, M. Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL). *Retrovirology* 2005, 2. [CrossRef] [PubMed]

25. Cabral, F.; Arruda, L.B.; de Araújo, M.L.; Montanheiro, P.; Smid, J.; de Oliveira, A.C.; Duarte, A.J.; Casseb, J. Detection of human T-cell lymphotropic virus type 1 in plasma samples. *Virus Res.* 2012, 163, 87–90. [CrossRef] [PubMed]

26. Journo, C.; Mahieux, R. HTLV-1 and innate immunity. *Viruses* 2011, 3, 1374–1394. [CrossRef] [PubMed]

27. Nagai, M.; Yamano, Y.; Brennan, M.B.; Mora, C.A.; Jacobson, S. Increased HTLV-I proviral load and preferential expansion of HTLV-I Tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP. *Ann. Neurol.* 2001, 50, 807–812. [CrossRef] [PubMed]
28. Gallo, R.C. Research and discovery of the first human cancer virus, HTLV-1. Best Pract. Res. Clin. Haematol. 2011, 24, 559–565. [CrossRef] [PubMed]

29. Morgan, O. HTLV-1 associated myelopathy/tropical spastic paraparesis: How far have we come? West Indian Med. J. 2011, 60, 505–512. [PubMed]

30. Ahuja, J.; Lepoutre, V.; Wigdahl, B.; Khan, Z.K.; Jain, P. Induction of pro-inflammatory cytokines by human T-cell leukemia virus type-1 Tax protein as determined by multiplexed cytokine protein array analyses of human dendritic cells. Biomed. Pharmacother. 2007, 61, 201–208. [CrossRef] [PubMed]

31. Yamano, Y.; Araya, N.; Sato, T.; Utsunomiya, A.; Azakami, K.; Hasegawa, D.; Izumi, T.; Fujita, H.; Aratani, S.; Yagishita, N.; et al. Abnormally high levels of virus-infected INF-γ+CCR4+CD4+CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. PLoS ONE 2009, 4. [CrossRef] [PubMed]

32. Olière, S.; Douville, R.; Sze, A.; Belgnouai, S.M.; Hiscott, J. Modulation of innate immune responses during human T-cell leukemia virus (HTLV-1) pathogenesis. Cytokine Growth Factor Rev. 2011, 22, 197–210. [CrossRef] [PubMed]

33. Puccioni-Sohler, M.; Gasparetto, E.; Cabral-Castro, M.J.; Slatter, C.; Vidal, C.M.; Cortes, R.D.; Rosen, B.R.; Mainiero, C. HAM/TSP: Association between white matter lesions on magnetic resonance imaging, clinical and cerebrospinal fluid findings. Arq. Neuropsiquiatr. 2012, 70, 246–251. [CrossRef] [PubMed]

34. Tamiya, T.; Kashiwagi, I; Takahashi, R.; Yasukawa, H.; Yoshimura, A. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol. 2009, 30, 592–602. [CrossRef] [PubMed]

35. Santos, S.B.; Muniz, A.L.; Carvalho, E.M. HTLV-1-associated myelopathy Immunopathogenesis. Gaz. Méd. Bahia 2009, 79, 11–17.

36. Palmer, D.C.; Restifo, N.P. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol. 2009, 30, 592–602. [CrossRef] [PubMed]

37. Tamiya, T.; Kashiwagi, I; Takahashi, R.; Yasukawa, H.; Yoshimura, A. Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: Regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 980–985. [CrossRef] [PubMed]
48. Yoshimura, A.; Suzuki, M.; Sakaguchi, R.; Hanada, T.; Yasukawa, H. SOCS, inflammation, and autoimmunity. *Front. Immunol.* 2012, 12. [CrossRef] [PubMed]

49. Nishiura, Y.; Nakamura, T.; Fukushima, N.; Moriuchi, R.; Katamine, S.; Eguchi, K. Increased mRNA expression of Th1-cytokine signaling molecules in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. *Tohoku J. Exp. Med.* 2004, 204, 289–298. [CrossRef] [PubMed]

50. Araújo, A.Q.; Leite, A.C.; Lima, M.A.; Silva, M.T. HTLV-1 and neurological conditions: When to suspect and when to order a diagnostic test for HTLV-1 infection? *Arq. Neuropsiquiatr.* 2009, 67, 132–138. [CrossRef] [PubMed]

51. Castro-Costa, C.M.; Araújo, A.Q.; Câmara, C.C.; Ferreira, A.S.; Santos, T.J.; Castro-Costa, S.B.; Alcântara, R.N.; Taylor, G.P. Pain in tropical spastic paraparesis/HTLV-I associated myelopathy patients. *Arq. Neuropsiquiatr.* 2009, 67, 866–870. [CrossRef] [PubMed]

52. Heraud, J.M.; Merien, F.; Mortreux, F.; Mahieux, R.; Kazanji, M. Immunological changes and cytokine gene expression during primary infection with human T-cell leukaemia virus type 1 in squirrel monkeys (*Saimiri sciureus*). *Virology* 2007, 361, 402–411. [CrossRef] [PubMed]

53. Michaelsen, J.; Barbosa, H.M.; Jordan, K.A.; Chapman, J.M.; Brunialti, M.K.; Neto, W.K.; Nukui, Y.; Sabino, E.C.; Chieia, M.A.; Oliveira, A.S.; et al. The frequency of CD127low expressing CD4+CD25high T regulatory cells is inversely correlated with human T lymphotropic virus type-1 (HTLV-1) proviral load in HTLV-1-infection and HTLV-1-associated myelopathy/tropical spastic paraparesis. *BMC Immunol.* 2008, 9. [CrossRef] [PubMed]

54. Montes, M.; Sanchez, C.; Verdonck, K.; Lake, J.E.; Gonzalez, E.; Lopez, G.; Terashima, A.; Nolan, T.; Lewis, D.E.; Gotuzzo, E.; et al. Regulatory T cell expansion in HTLV-1 and Strongyloides co-infection is associated with reduced IL-5 responses to Strongyloides stercoralis antigen. *PLoS Negl. Trop. Dis.* 2009, 3. [CrossRef] [PubMed]

55. Santos, S.B.; Porto, A.F.; Muniz, A.L.; Jesus, A.R.; Magalhães, E.; Melo, A.; Dutra, W.O.; Gollob, K.J.; Carvalho, E.M. Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers. *BMC Infect. Dis.* 2004, 4. [CrossRef]

56. Brito-Melo, G.E.; Martins-Filho, O.A.; Carneiro-Proietti, A.B.; Catalão-Soares, B.; Ribas, J.G.; Thorum, G.W.; Barbosa-Stancioli, E.F. Phenotypic study of peripheral blood leucocytes in HTLV-I infected individuals from Minas Gerais, Brazil. *Scand. J. Immunol.* 2002, 55, 621–628. [CrossRef] [PubMed]

57. Coutinho, R.J.; Grassi, M.F.; Korngold, A.B.; Olavarria, V.N.; Galvão-Castro, B.; Mascarines, R.E. Human T lymphotropic virus type 1 (HTLV-1) proviral load induces activation of T-lymphocytes in asymptomatic carriers. *BMC Infect. Dis.* 2014, 22. [CrossRef] [PubMed]

58. Walker, L.S.; Abbas, A.K. The enemy within: Keeping self-reactive T cells at bay in the periphery. *Nat. Rev. Immunol.* 2002, 2, 11–19. [CrossRef] [PubMed]

59. O’Garra, A.; Vieira, P. Regulatory T cells and mechanisms of immune system control. *Nat. Med.* 2004, 10, 801–805. [CrossRef] [PubMed]

60. Moudgil, K.D.; Choubey, D. Cytokines in autoimmunity: Role in induction, regulation, and treatment. *J. Interferon Cytokine Res.* 2011, 31, 695–703. [CrossRef] [PubMed]

61. Parks, C.G.; Miller, F.W.; Pollard, K.M.; Selmi, C.; Germolec, D.; Joyce, K.; Rose, N.R.; Humble, M.C. Expert panel workshop consensus statement on the role of the environment in the development of autoimmune disease. *Int. J. Mol. Sci.* 2014, 15, 14269–14297. [CrossRef] [PubMed]

62. Cárdenas-Roldán, J.; Rojas-Villarraga, A.; Anaya, J.M. How do autoimmune diseases cluster in families? A systematic review and meta-analysis. *BMC Med.* 2013, 73. [CrossRef]

63. Lossius, A.; Johansen, J.N.; Torkildsen, O.; Vartdal, F.; Holmøy, T. Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis-association and causation. *Viruses* 2012, 4, 3701–3730. [CrossRef] [PubMed]

64. Getts, D.R.; Chastain, E.M.; Terry, R.L.; Miller, S.D. Virus infection, antiviral immunity, and autoimmunity. *Immunol. Rev.* 2013, 255, 197–209. [CrossRef] [PubMed]

65. Levin, M.C.; Lee, S.M.; Kalume, F.; Morecos, Y.; Dohan, F.C.; Hasty, K.A.; Callaway, J.C.; Zunt, J.; Desiderio, D.; Stuart, J.M. Autoimmunity due to molecular mimicry as a cause of neurological disease. *Nat. Med.* 2002, 8, 509–513. [CrossRef] [PubMed]
66. García-Vallejo, F.; Domínguez, M.C.; Tamayo, O. Autoimmunity and molecular mimicry in tropical spastic paraparesis/human T-lymphotropic virus-associated myelopathy. Braz. J. Med. Biol. Res. 2005, 38, 241–250. [PubMed]

67. Alamanos, Y.; Voulgari, P.V.; Drosos, A.A. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: A systematic review. Semin. Arthritis Rheum. 2006, 36, 182–188. [CrossRef] [PubMed]

68. Mota, L.M.H.; Laurindo, I.M.M.; Santos Neto, L.L. Artrite reumatoide inicial–conceitos. Rev. Assoc. Med. Bras. 2010, 56, 227–229. [CrossRef] [PubMed]

69. Coenen, M.J.H.; Gregersen, P.K. Rheumatoid arthritis: A view of the current genetic landscape. Genes Immun. 2008, 77, 1–11. [CrossRef] [PubMed]

70. Firestein, G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 5, 356–361. [CrossRef] [PubMed]

71. Feldmann, M.; Brennan, F.M. Rheumatoid arthritis. Cell 1996, 85, 307–310. [CrossRef]

72. Meyer, P.W.; Hodkinson, B.; Ally, M.; Musenge, E.; Wadee, A.A.; Fickl, H.; Tikly, M.; Anderson, R. Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis. Med. Inflamm. 2010, 2010. [CrossRef] [PubMed]

73. Steiner, G.; Tohidast-Akrad, M.; Witzmann, G.; Vesely, M.; Studnicka-Benke, A.; Gal, A.; Kunaver, M.; Zenz, P.; Smolen, J.S. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology 1999, 38, 202–213. [CrossRef] [PubMed]

74. Nishioka, K.; Nakajima, T.; Hasunuma, T.; Sato, K. Rheumatic manifestation of human leukemia virus infection. Rheum. Dis. Clin. N. Am. 1993, 19, 489–503.

75. Yakova, M.; Lézin, A.; Dantin, F.; Lagathu, G.; Olindo, S.; Jean-Baptiste, G.; Arfi, S.; Césaire, R. Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease. Retrovirology 2005, 1. [CrossRef]

76. Firestein, G.S.; Zvaifler, N.J. Rheumatoid arthritis: A disease of disordered immunity. In Inflammation: Basic Principles and Clinical Correlates, 2nd ed.; Raven Press Ltd.: New York, NY, USA, 1992; pp. 959–975.

77. Eguchi, K.; Origuchi, T.; Takashima, H.; Iwata, K.; Katamine, S.; Nagataki, S. High seroprevalence of anti-HTLV-1 antibody in rheumatoid arthritis. Arthritis Rheum. 1996, 39, 463–466. [CrossRef] [PubMed]

78. Brzustewicz, E.; Bryl, E. The role of cytokines in the pathogenesis of rheumatoid arthritis—Practical and potential application of cytokines as biomarkers and targets of personalized therapy. Cytokine 2015, 76, 527–536. [CrossRef] [PubMed]

79. Iijichi, S.; Matsuda, T.; Maruyama, I.; Izumiara, T.; Kojima, K.; Niimura, T.; Maruyama, Y.; Sonoda, S.; Yoshida, A.; Osame, M. Arthritis in a human T lymphotropic virus type I (HTLV-I) carrier. Ann. Rheum. Dis. 1990, 49, 718–721. [CrossRef] [PubMed]

80. Fox, R.J.; Tornwall, J.; Maruyama, T.; Stern, M. Evolving concepts of diagnosis, pathogenesis, and therapy of Sjögren’s syndrome. Curr. Opin. Rheumatol. 1998, 10, 446–456. [CrossRef] [PubMed]

81. Ambrosi, A.; Wahren-Herlenius, M. Update on the immunobiology of Sjögren’s syndrome. Curr. Opin. Rheumatol. 2015, 27, 468–475. [CrossRef] [PubMed]

82. Eguchi, K.; Matsuoka, N.; Ida, H.; Nakashima, M.; Sakai, M.; Sakito, S.; Kawakami, A.; Terada, K.; Shimada, H.; Kawabe, Y. Primary Sjögren’s syndrome with antibodies to HTLV-I carrier. Ann. Rheum. Dis. 1990, 49, 718–721. [CrossRef] [PubMed]

83. Vernant, J.C.; Buisson, G.; Magdeleine, J.; Thore, J.; Jouannelle, A.; Neisson-Vernant, C.; Monplaisir, N. T-lymphocyte alveolitis, tropical spastic paraparesis, and Sjögren syndrome. Lancet 1988, 1. [CrossRef]

84. Nakamura, H.; Takahashi, Y.; Yamamoto-Fukuda, T.; Horai, Y.; Nakashima, Y.; Arima, K.; Nakamura, T.; Koji, T.; Kawakami, A. Direct infection of primary salivary gland epithelial cells by human T lymphotrophic virus type I in patients with Sjögren’s syndrome. Arthritis Rheumatol. 2015, 67, 1096–1106. [CrossRef] [PubMed]

85. Scofield, L.; Alarçon, G.S.; Cooper, G.S. Employment and disability issues in systemic lupus erythematosus: A review. Arthritis Care Res. 2008, 59, 1475–1479. [CrossRef] [PubMed]

86. Cooper, G.S.; Gilbert, K.M.; Greidinger, E.L.; James, J.A.; Pfau, J.C.; Reinlib, L.; Richardson, B.C.; Rose, N.R. Recent advances and opportunities in research on lupus: Environmental influences and mechanisms of disease. Cien. Saude Colet. 2008, 14, 1865–1876. [CrossRef] [PubMed]

87. Tiffin, N.; Adeyemo, A.; Okpechi, I. A diverse array of genetic factors contribute to the pathogenesis of systemic lupus erythematosus. Orphanet J. Rare Dis. 2013, 7. [CrossRef] [PubMed]
88. Yap, D.Y.; Lai, K.N. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: From basics to recent advances. *J. Biomed. Biotechnol.* 2010, 2010. [CrossRef] [PubMed]

89. Shirdel, A.; Hashemzadeh, K.; Sahebari, M.; Rafatpanah, H.; Hatif, M.; Rezaieyazdi, Z.; Mirfeizi, Z.; Faridhosseini, R. Is there any association between human lymphotropic virus type I (HTLV-I) infection and systemic lupus erythematosus? *Iran. J. Basic Med. Sci.* 2013, 16, 252–257. [PubMed]

90. Sugimoto, T.; Okamoto, M.; Koyama, T.; Takashima, H.; Saeki, M.; Kashiwagi, A.; Horie, M. The occurrence of systemic lupus erythematosus in an asymptomatic carrier of human T-cell lymphotropic virus type I. *Clin. Rheumatol.* 2007, 26, 1005–1007. [CrossRef] [PubMed]

91. Akimoto, M.; Matsushita, K.; Suruga, Y.; Aoki, N.; Ozaki, A.; Uozumi, K.; Tei, C.; Arima, N. Clinical manifestations of human T lymphotropic virus type I-infected patients with systemic lupus erythematosus. *J. Rheumatol.* 2007, 34, 1841–1848. [PubMed]

92. Magistrelli, C.; Samoilova, E.; Agarwal, R.K.; Banki, K.; Ferrante, P.; Vladutiu, A.; Phillips, P.E.; Perl, A. Polymorphic genotypes of the HRES-1 human endogenous retrovirus locus correlate with systemic lupus erythematosus and autoreactivity. *Immunogenetics* 1999, 49, 829–834. [CrossRef] [PubMed]

93. Olsen, R.G.; Tarr, M.J.; Mathes, L.E.; Whisler, R.; du Plessis, D.; Schulz, E.J.; Blakeslee, J.R. Serological and virological evidence of human T-lymphotropic virus in systemic lupus erythematosus. *Med. Microbiol. Immunol.* 1987, 176, 53–64. [CrossRef] [PubMed]

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).